Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. Keeping that in mind, here are two stocks where you should be greedy instead of fearful and one facing legitimate challenges.

One Stock to Sell:

Brighthouse Financial (BHF)

Consensus Price Target: $65.50 (10.4% implied return)

Spun off from MetLife in 2017 to focus specifically on retail financial products, Brighthouse Financial (NASDAQ: BHF) provides annuity contracts and life insurance products designed to help individuals protect wealth, generate income, and transfer assets.

Why Do We Steer Clear of BHF?

1. Insurance offerings face significant market challenges this cycle as net premiums earned contracted by 7.7% annually over the last five years
2. Policy losses and capital returns have eroded its book value per share this cycle as its book value per share declined by 11.1% annually over the last five years
3. Debt-to-equity ratio of 1.3× shows the firm has taken on excessive debt, leaving little room for error

Brighthouse Financial’s stock price of $59.36 implies a valuation ratio of 0.7x forward P/B. Read our free research report to see why you should think twice about including BHF in your portfolio.

Two Stocks to Watch:

Teradyne (TER)

Consensus Price Target: $314.18 (6.7% implied return)

Sporting most major chip manufacturers as its customers, Teradyne (NASDAQ: TER) is a US-based supplier of automated test equipment for semiconductors as well as other technologies and devices.

Why Does TER Stand Out?

1. Demand for the next 12 months is expected to accelerate above its two-year trend as Wall Street forecasts robust revenue growth of 31.5%
2. Offerings are difficult to replicate at scale and lead to a stellar gross margin of 58.3%
3. Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures

At $294.50 per share, Teradyne trades at 48.5x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Pfizer (PFE)

Consensus Price Target: $28.54 (5.6% implied return)

With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE: PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions.

Why Do We Like PFE?

1. Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 10.1% over the past two years
2. Massive revenue base of $62.58 billion in a highly regulated sector makes the company difficult to replace, giving it meaningful negotiating power
3. Adjusted operating margin improvement of 17.8 percentage points over the last two years demonstrates its ability to scale efficiently

Pfizer is trading at $27.02 per share, or 9.3x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.